HilleVax (NASDAQ:HLVX) Shares Up 6.3%

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report)'s share price traded up 6.3% on Monday . The company traded as high as $13.10 and last traded at $13.08. 16,897 shares changed hands during trading, a decline of 88% from the average session volume of 136,215 shares. The stock had previously closed at $12.30.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $28.00 target price on shares of HilleVax in a report on Thursday, March 21st.

HilleVax Stock Up 5.5 %

The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $645.37 million, a PE ratio of -4.35 and a beta of 0.65. The firm's fifty day moving average is $16.03 and its 200-day moving average is $14.63.

HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.02. On average, equities research analysts predict that HilleVax, Inc. will post -3.22 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Aditya Kohli sold 8,866 shares of the firm's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $132,369.38. Following the completion of the sale, the director now owns 812,878 shares in the company, valued at $12,136,268.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other HilleVax news, Director Aditya Kohli sold 8,866 shares of the company's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $132,369.38. Following the sale, the director now owns 812,878 shares of the company's stock, valued at $12,136,268.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shane Maltbie sold 3,576 shares of HilleVax stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $53,389.68. Following the transaction, the chief financial officer now directly owns 40,656 shares of the company's stock, valued at approximately $606,994.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,039 shares of company stock worth $986,464,242. Corporate insiders own 29.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Deerfield Management Company L.P. Series C increased its position in HilleVax by 20.3% during the third quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company's stock worth $53,857,000 after buying an additional 675,000 shares in the last quarter. Monashee Investment Management LLC purchased a new position in HilleVax in the 3rd quarter valued at about $1,480,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of HilleVax during the third quarter worth about $2,374,000. Maven Securities LTD acquired a new position in shares of HilleVax in the third quarter valued at approximately $478,000. Finally, Swiss National Bank lifted its stake in shares of HilleVax by 47.2% during the third quarter. Swiss National Bank now owns 31,200 shares of the company's stock valued at $420,000 after buying an additional 10,000 shares during the period. 86.42% of the stock is owned by hedge funds and other institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.